blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2245067

EP2245067 - METHODS OF USING CADHERIN 11 (CDH11) ANTAGONISTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.11.2013
Database last updated on 19.10.2024
Most recent event   Tooltip01.11.2013Application deemed to be withdrawnpublished on 04.12.2013  [2013/49]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2010/44]
Inventor(s)01 / SAINT-MEZARD, Pierre
Novartis Pharma AG Postfach
4002 Basel / CH
 [2010/44]
Representative(s)Kassow, Anders
Novartis Pharma AG
Patent Department
4002 Basel / CH
[N/P]
Former [2010/44]Kassow, Anders
Novartis Pharma AG Patent Department
4002 Basel / CH
Application number, filing date09711479.709.02.2009
[2010/44]
WO2009EP51467
Priority number, dateUS2008006538111.02.2008         Original published format: US 65381
[2010/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009101059
Date:20.08.2009
Language:EN
[2009/34]
Type: A2 Application without search report 
No.:EP2245067
Date:03.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 20.08.2009 takes the place of the publication of the European patent application.
[2010/44]
Search report(s)International search report - published on:EP17.06.2010
ClassificationIPC:C07K16/28, A61P13/12, A61P37/06
[2010/44]
CPC:
C07K14/705 (EP,US); A61P1/16 (EP); A61P11/00 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P19/02 (EP);
A61P37/06 (EP); A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/44]
TitleGerman:VERFAHREN ZUR VERWENDUNG VON CADHERIN 11 (CDH11)-ANTAGONISTEN[2010/44]
English:METHODS OF USING CADHERIN 11 (CDH11) ANTAGONISTS[2010/44]
French:PROCÉDÉS D'UTILISATION D'ANTAGONISTES DE LA CADHÉRINE 11 (CDH11)[2010/44]
Entry into regional phase13.09.2010National basic fee paid 
17.12.2010Designation fee(s) paid 
17.12.2010Examination fee paid 
Examination procedure04.11.2010Amendment by applicant (claims and/or description)
17.12.2010Examination requested  [2011/04]
13.02.2013Despatch of a communication from the examining division (Time limit: M04)
25.06.2013Application deemed to be withdrawn, date of legal effect  [2013/49]
31.07.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2013/49]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.02.2013
Fees paidRenewal fee
15.02.2011Renewal fee patent year 03
15.02.2012Renewal fee patent year 04
28.02.2013Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]  - FORINO MONICA ET AL, "TGF beta 1 induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture", INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, (200606), vol. 87, no. 3, ISSN 0959-9673, pages 197 - 208, XP002553818 [X] 1,2 * the whole document * [Y] 3-18

DOI:   http://dx.doi.org/10.1111/j.1365-2613.2006.00479.x
 [Y]  - WYNN T A, "Cellular and molecular mechanisms of fibrosis", JOURNAL OF PATHOLOGY, (200801), vol. 214, no. 2, ISSN 0022-3417, pages 199 - 210, XP002553819 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1002/path.2277
 [Y]  - BEDI ET AL, "Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis", TRANSPLANTATION REVIEWS, GRUNE & STRATTON, ORLANDO, FL, US, (20071123), vol. 22, no. 1, ISSN 0955-470X, pages 1 - 5, XP022353103 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.trre.2007.09.004
 [Y]  - WARD ET AL, "Hypothesis: Epithelial-to-Mesenchymal Transition is a Common Cause of Chronic Allograft Failure", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, (20050418), vol. 37, no. 2, ISSN 0041-1345, pages 977 - 980, XP022309686 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.transproceed.2004.12.203
 [Y]  - HERTIG A ET AL, "Risk factors for early epithelial to mesenchymal transition in renal grafts", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD, DK, vol. 6, no. 12, ISSN 1600-6135, (20061201), pages 2937 - 2946, (20061025), XP009125335 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1600-6143.2006.01559.x
 [Y]  - BINKLEY CHARLES E ET AL, "The molecular basis of pancreatic fibrosis - Common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma", PANCREAS, RAVEN PRESS, NEW YORK, NY, US, (20041101), vol. 29, no. 4, ISSN 0885-3177, pages 254 - 263, XP009125254 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1097/00006676-200411000-00003
 [Y]  - ZEISBERG ELISABETH M ET AL, "Endothelial-to-mesenchymal transition contributes to cardiac fibrosis", NATURE MEDICINE, (200708), vol. 13, no. 8, ISSN 1078-8956, pages 952 - 961, XP002553821 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm1613
 [Y]  - LIU Y, "Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, (20040101), vol. 15, no. 1, ISSN 1046-6673, pages 1 - 12, XP003015975 [Y] 2-18 * the whole document *

DOI:   http://dx.doi.org/10.1097/01.ASN.0000106015.29070.E7
 [DA]  - VASKO VASILY ET AL, "Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (200702), vol. 104, no. 8, ISSN 0027-8424, pages 2803 - 2808, XP002555393 [DA] * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.0610733104
 [A]  - LEE DAVID M ET AL, "Cadherin-11 in synovial lining formation and pathology in arthritis", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 315, no. 5814, ISSN 1095-9203, (20070216), pages 1006 - 1010, (20070125), XP002528086 [A] * the whole document *

DOI:   http://dx.doi.org/10.1126/SCIENCE.1137306
 [A]  - TOMITA KYOICHI ET AL, "Cadherin switching in human prostate cancer progression", CANCER RESEARCH, (20000701), vol. 60, no. 13, ISSN 0008-5472, pages 3650 - 3654, XP002555394 [A] * the whole document *
 [A]  - PISHVAIAN M J ET AL, "CADHERIN-11 IS EXPRESSED IN INVASIVE BREAST CANCER CELL LINES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, (19990815), vol. 59, no. 4, ISSN 0008-5472, pages 947 - 952, XP000877301 [A] * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.